Skip to search formSkip to main contentSkip to account menu

EP2306

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsMorpholines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors.
Although treatment with statins significantly reduces adverse cardiovascular outcomes, several studies have shown that… 
2009
2009
Abstract: 579 PRECLINICAL CHARACTERIZATION OF SQUALENE SYNTHASE INHIBITORS EP2306 AND EP2302
2008
2008
Antiatherosclerotic Properties of EP2302, a Novel Squalene Synthase Inhibitor, in the Cholesterol-fed Rabbit
EP2302 is a novel nitric oxide donor compound that inhibits squalene synthase. We hypothesized that EP2302 can reduce… 
2007
2007
EP2306 [2-(4-Biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], A Novel Squalene Synthase Inhibitor, Reduces Atherosclerosis in the Cholesterol-Fed Rabbit
EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide] inhibits squalene synthase and lipid biosynthesis… 
2007
2007
EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells.
EP2306 and EP2302 are two novel squalene synthase inhibitors with hypolipidemic, antiatherosclerotic, and antioxidant properties… 
2005
2005
W12-P-074 Inhibition of squalene synthase activity and lipid biosynthesis by EP2306 and EP2302, two novel 2-biphenylmorpholine compounds
2004
2004
Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)